ArticleUltrasonics sonochemistry2026
Sonocrystallization approach in crystal habit modification for improving the pharmaceutical properties of Rivaroxaban.
Article in Ultrasonics sonochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor pharmaceutical material properties of active pharmaceutical ingredients (APIs) can result in suboptimal manufacturing and therapeutic outcomes. Rivaroxaban (RIV) was explored as a model API due to its poor pharmaceutical properties and challenging industrial processability. In this research, crystal habit modification (CHM) of RIV was explored via solvent evaporation, cooling crystallization, and sonocrystallization methods. RIV (irregular) habit was modified to cuboidal, plate, and fiber via solvent evaporation; however, these were not further explored due to their large crystal sizes (>400 µm), which could pose serious dissolution and dose uniformity issues. Cooling crystallization method yielded plate (RIV_ACT) and blade-shaped (RIV_ACN) crystals with sizes < 200 µm. Further, CHM by sonocrystallization yielded tabular (RIV_SN6) crystals < 10 µm in size, which also exhibit a lower aspect ratio, a lower span value, and a narrower crystal size distribution than RIV_ACT and RIV_ACN. No polymorphic changes in modified habits were observed, as confirmed by PXRD, DSC, and TGA. Powder flowability improved significantly in the RIV_SN6 than in RIV_ACT and RIV_ACN (p < 0.0001) due to its narrow crystal size distribution. Interestingly, the RIV_SN6 showed improved tensile strength (p < 0.05) at a compression force of 300 MPa and exhibited improved wettability due to the exposure of polar functional groups on the modified habits. Furthermore, significant improvements in polar energy (p < 0.05) and ∼1.88 fold of IDR (p < 0.0001) were observed in RIV_SN6 compared to the RIV_ACT and RIV_ACN due to the prominence of polar groups and hydrophilic components on the particular facet.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.